2020
DOI: 10.1590/0102-672020200003e1534
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background: Colorectal cancer (CRC) is one of the most common types of cancer in the world. Over time, intestinal epithelial cells undergo mutations that may lead to proliferative advantage and the emergence of cancer. Mutations in the beta-catenin pathway are amongst those described in the development of CRC. Aim: To verify the existence of a relation between the presence of Wnt3, beta-catenin and CDX2 in colorectal cancer samples and clinical outcomes such as disease progression or death. Method: Wnt3a, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 19 publications
0
1
0
Order By: Relevance
“…For the diagnosis of primary CRC in resection specimen, CDX2 is not frequently used, because the vast majority of CRCs are accompanied by adenomatous precursor lesions that are diagnostic of primary CRC in combination with a morphologically compatible invasive carcinoma component. However, CDX2 gained increasing attention in the scientific community in recent years as some studies proposed a lost or diminished expression of CDX2 as an independent biomarker of a more aggressive disease course [17,18,21,23,26], while other studies could not generally confirm these results [31][32][33][34][35][36][37]. Compared to CDX2, which is normally assessed via immunohistochemistry, the recent WHO classification from 2019 defines the different histomorphological subtypes of CRC, tumour budding activity and the traditional WHO-grading algorithm in its essential diagnostic criteria for CRC, which represent purely histomorphological parameters that are assessed through the evaluation of HE-stained slides.…”
Section: Discussionmentioning
confidence: 99%
“…For the diagnosis of primary CRC in resection specimen, CDX2 is not frequently used, because the vast majority of CRCs are accompanied by adenomatous precursor lesions that are diagnostic of primary CRC in combination with a morphologically compatible invasive carcinoma component. However, CDX2 gained increasing attention in the scientific community in recent years as some studies proposed a lost or diminished expression of CDX2 as an independent biomarker of a more aggressive disease course [17,18,21,23,26], while other studies could not generally confirm these results [31][32][33][34][35][36][37]. Compared to CDX2, which is normally assessed via immunohistochemistry, the recent WHO classification from 2019 defines the different histomorphological subtypes of CRC, tumour budding activity and the traditional WHO-grading algorithm in its essential diagnostic criteria for CRC, which represent purely histomorphological parameters that are assessed through the evaluation of HE-stained slides.…”
Section: Discussionmentioning
confidence: 99%